Low-concentration atropine medicine-containing eye drop and preparation method thereof

A technology of atropine and eye drops, which is applied in the direction of medical formula, drug combination, drug delivery, etc., can solve the problems of unclear explanation of the use of eye drops, no clinical efficacy, eye damage, etc. Effects of myopia, avoidance of damage and stimuli

Inactive Publication Date: 2017-12-12
杭州赫尔斯科技有限公司
View PDF2 Cites 25 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, during the preparation, production and long-term storage of low-concentration atropine drug eye drops, due to the ester bond contained in the atropine drug molecule, it is unstable. If it is not handled properly, it will be affected by temperature, light, solution pH, storage time etc., and the solution will deteriorate or even fail to produce corresponding alcohol or acid. These products have no clinical efficacy, and when patients use the deteriorated eye drops, there may be certain safety hazards and side effects
[0007] Many eye drops currently on the market, in order to maintain sterility and shelf life, add bacteriostatic agents and trace elemen

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0048] In addition, the present invention also provides a method for preparing low-concentration atropine eye drops, which comprises the following steps:

[0049] a. The atropine drugs are formulated into an aqueous solution with a concentration of 0.001% to 1% (w / v),

[0050] b. Then add 0% to 10% (w / v) of the solute with lubricating, solubilizing and moisturizing effects to the solution obtained in step a, and mix it evenly,

[0051] c. Then add an acid-base regulator to the solution obtained in step b, and adjust its pH to 6.0 to 8.0,

[0052] d. adding an osmotic pressure buffer to the solution obtained in step c, and adjusting its osmotic pressure to 280~380mOsm / L,

[0053] e. Add thickener to the solution obtained in step d, adjust its viscosity to 6~10mps,

[0054] f. adding 0.001%-1% (w / v) of a solute having the effect of stabilizing atropine drugs to the solution obtained in step e;

[0055] g. finally adding 0%~0.1% (w / v) bacteriostatic agent and optional 0%~0.1% ...

Embodiment 1

[0060] Atropine sulfate was added to the water for injection to prepare an aqueous solution with a concentration of 0.001% (w / v), and then glycerol was added to the solution to make the concentration 0.01% (w / v). After mixing, vitamin E was added. , its concentration is 0.01% (w / v), the pH is adjusted to 7.5 with sodium carbonate-sodium bicarbonate buffer solution, the osmotic pressure is adjusted to 303 mOsm / L with sodium chloride, and the viscosity is adjusted to hydroxypropyl methylcellulose to 9.0mps, sterilized by 0.22μm membrane filtration, and then single-dose aseptic filling to obtain sterile low-concentration atropine sulfate eye drops.

Embodiment 2

[0062] The bulk drug atropine sulfate was added to water for injection to prepare an aqueous solution with a concentration of 0.01% (w / v), and polyethylene glycol was added to the solution to make the concentration 0.02% (w / v), and after mixing uniformly, Add taurine to make its concentration 1% (w / v), adjust the pH to 6.9 with sodium hydrogen phosphate-sodium dihydrogen phosphate buffer solution, adjust the osmotic pressure to 310mOsm / L with glucose, and adjust the viscosity with sodium hyaluronate It is 7.6mps, sterilized by hot pressing, and then aseptically filled with a single dose to obtain sterile low-concentration atropine sulfate eye drops.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A low-concentration atropine medicine-containing eye drop comprises the following components: (A) 0.001-1% (w/v) of an atropine medicine, (B) 0-10% (w/v) of a solute with the effects of lubricating, solubilizing and moisturizing, (C) an acidity and alkalinity regulating agent of which the amount is proper to ensure that the pH is regulated to 6.0-8.0, (D) an osmotic pressure buffering agent of which the amount is proper to ensure that the osmotic pressure is regulated to 280-380 mOsm/L, (E) a thickener of which the amount is proper to ensure that the viscosity is regulated to 6-10 mps, (F) 0.001-1% (w/v) of a solute with an atropine medicine stabilizing effect, (G) 0-0.1% (w/v) of a bacteriostatic agent, 0-0.1% (w/v) of one or more of mint, natural borneol, vitamin B6, dipotassium glycyrrhizinate or other substances with auxiliary effects which can be also optionally added under the premise that the safety is ensured and the efficacy of the main medicine is not affected, and the balance of water. The eye drop is good in stability of the main medicine and safe, is unlikely to be contaminated by microorganisms, and can effectively prevent and relieve juvenile myopia.

Description

technical field [0001] The invention relates to atropine drug eye drops, in particular to a low-concentration atropine drug eye drop and a preparation method thereof. Background technique [0002] Eyes are one of the most important organs of human beings and provide a guarantee for people to adapt to social life. With the improvement of people's living standards and the accelerated pace of life, all kinds of electronic products have become necessities of life. People are increasingly relying on computers, TVs and other video display terminals for various activities. People spend more time with their eyes than in the past. Several times more in ten years, less and less time for eyes to rest. Especially for teenagers and children, with the progress of society, the learning tasks are becoming more and more heavy, there is very little time for extracurricular activities, and the time for learning, reading, writing, etc. is getting longer and longer, continuous long-term work or...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/08A61K31/46A61P27/10A61K31/045A61K31/4415A61K31/704A61K36/534
CPCA61K9/0048A61K9/08A61K31/045A61K31/4415A61K31/46A61K31/704A61K36/534A61K2300/00
Inventor 李大伟周光大林建华
Owner 杭州赫尔斯科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products